Kiran Mazumdar-Shaw, 

At a time when the broader pharmaceutical industry faced challenges, the Bengaluru-based biopharmaceutical company had a stellar year. Its revenue for FY19 rose 31% to ₹5,659 crore, while net profit was up 143% at ₹905 crore. Under Mazumdar-Shaw’s stewardship, Biocon saw robust growth in its biologics, research services, and small molecules businesses. The company pioneered the launch of biosimilar drugs in important global markets such as the U.S. and Europe. Using biosimilars to treat diseases such as cancer, diabetes, and autoimmune ailments, Biocon served close to two million patients in FY19.